Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MIRELIS ACOSTA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1093961609
CMS profile
992761
Location
SAN JUAN, PR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$15,004.72

125 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MIRELIS ACOSTA

NPI 1093961609 · CMS profile ID 992761

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SAN JUAN, PR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093961609?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MIRELIS ACOSTA, NPI 1093961609, CMS profile ID 992761. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093961609?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MIRELIS ACOSTA, NPI 1093961609, CMS profile ID 992761. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093961609?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MIRELIS ACOSTA, NPI 1093961609, CMS profile ID 992761, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–125 of 125 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1093961609?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

125 matching records · $15,004.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 125 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–125 of 125.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $16.1904/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843662593 CMS
Taiho Oncology, Inc. $21.1804/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843382059 CMS
AbbVie Inc. $25.0004/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793799751 CMS
Janssen Pharmaceuticals, Inc $17.6504/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787748355 CMS
Eli Lilly Export S.A. Puerto Rico Branch $22.9503/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818612855 CMS
Genentech USA, Inc. $20.0003/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835953797 CMS
Janssen Pharmaceuticals, Inc $16.5803/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787748474 CMS
AstraZeneca Pharmaceuticals LP $15.6503/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829775303 CMS
Exelixis Inc. $17.6503/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838868353 CMS
PBG PUERTO RICO LLC $22.9503/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832611559 CMS
AbbVie Inc. $25.0002/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 793799747 CMS
Eli Lilly Export S.A. Puerto Rico Branch $20.0002/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818665827 CMS
AstraZeneca Pharmaceuticals LP $14.6702/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829484273 CMS
E.R. Squibb & Sons, L.L.C. $13.3802/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783581465 CMS
Merck Sharp & Dohme Corporation $1,900.0002/17/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848531149 CMS
Eisai Inc. $19.9702/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817845991 CMS
E.R. Squibb & Sons, L.L.C. $600.0002/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783581589 CMS
E.R. Squibb & Sons, L.L.C. $600.0002/08/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783581593 CMS
Amgen Inc. $14.8502/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825632077 CMS
Bayer HealthCare Pharmaceuticals Inc. $17.6601/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789066179 CMS
Janssen Pharmaceuticals, Inc $15.2401/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787748401 CMS
Janssen Pharmaceuticals, Inc $20.5701/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787748377 CMS
E.R. Squibb & Sons, L.L.C. $17.2101/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783581455 CMS
Eli Lilly Export S.A. Puerto Rico Branch $19.9501/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818606653 CMS
E.R. Squibb & Sons, L.L.C. $22.2201/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783581457 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $55,255.75 268
PY2020 $14,256.60 129
PY2021 $15,004.72 125
PY2022 $19,015.42 159
PY2023 $18,597.65 149
PY2024 $13,739.37 169
PY2025 $18,552.52 174

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $272,928.82 41
PY2024 Principal investigator $776,395.24 51
PY2023 Principal investigator $1,189,320.31 53
PY2022 Principal investigator $1,540,472.88 33
PY2021 Recipient $1,910.15 2
PY2021 Principal investigator $880,604.20 33
PY2020 Recipient $708.70 1
PY2020 Principal investigator $857,624.67 95
PY2019 Recipient $11,257.00 3
PY2019 Principal investigator $650,651.37 30

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $725.12 12/31/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults with Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1202534471
Principal investigator 1 Merck Sharp & Dohme LLC $5,264.61 12/31/2025 Non-covered Recipient Entity
FDI Clinical Research
A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib E7080,MK-7902 with Pembrolizumab MK-3475 in Combination with Transarterial Chemoembolization TACE Versus TACE in P No dispute reported 06/30/2026 1232938254
Principal investigator 1 Merck Sharp & Dohme LLC $63,061.31 12/17/2025 Non-covered Recipient Entity
FDI Clinical Research
A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib E7080,MK-7902 with Pembrolizumab MK-3475 in Combination with Transarterial Chemoembolization TACE Versus TACE in P No dispute reported 06/30/2026 1232938252
Principal investigator 1 Merck Sharp & Dohme LLC $2,220.00 11/13/2025 Non-covered Recipient Entity
FDI Clinical Research
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1232926945
Principal investigator 1 Exelixis Inc. $2,000.00 11/07/2025 Non-covered Recipient Entity
Fundacion de Investigacion de Diego
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors No dispute reported 06/30/2026 1222380618
Principal investigator 1 Exelixis Inc. $1,867.30 11/07/2025 Non-covered Recipient Entity
Fundacion de Investigacion de Diego
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors No dispute reported 06/30/2026 1222380620
Principal investigator 1 Exelixis Inc. $14,000.00 11/07/2025 Non-covered Recipient Entity
Fundacion de Investigacion de Diego
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors No dispute reported 06/30/2026 1222380622
Principal investigator 1 Exelixis Inc. $3,000.00 11/07/2025 Non-covered Recipient Entity
Fundacion de Investigacion de Diego
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors No dispute reported 06/30/2026 1222380624
Principal investigator 1 Exelixis Inc. $3,000.00 11/07/2025 Non-covered Recipient Entity
Fundacion de Investigacion de Diego
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors No dispute reported 06/30/2026 1222380626
Principal investigator 1 Merck Sharp & Dohme LLC $1,700.00 11/03/2025 Non-covered Recipient Entity
FDI Clinical Research
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i No dispute reported 06/30/2026 1232926773
Principal investigator 1 ABBVIE INC. $4,500.00 10/20/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) No dispute reported 06/30/2026 1202517451
Principal investigator 1 TOLMAR, INC. $1,521.45 10/17/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC.
TOL2506A-EXT No dispute reported 06/30/2026 1237322324
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,750.00 10/15/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO, INC.
A Phase III Randomized Open-Label Sponsor-Blinded Multicenter Study of Durvalumab in Combination with Tremelimumab Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3) No dispute reported 06/30/2026 1185547619
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $32,961.70 09/18/2025 Non-covered Recipient Entity
Fdi Clinical Research
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies No dispute reported 06/30/2026 1235997407
Principal investigator 1 ABBVIE INC. $19,500.00 09/02/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) No dispute reported 06/30/2026 1202507015
Principal investigator 1 Merck Sharp & Dohme LLC $264.09 08/31/2025 Non-covered Recipient Entity
FDI Clinical Research
A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib E7080,MK-7902 with Pembrolizumab MK-3475 in Combination with Transarterial Chemoembolization TACE Versus TACE in P No dispute reported 06/30/2026 1232938256
Principal investigator 1 TOLMAR, INC. $742.50 07/18/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC.
TOL2506A-EXT No dispute reported 06/30/2026 1237322217
Principal investigator 1 TOLMAR, INC. $2,061.45 06/13/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC.
TOL2506A-EXT No dispute reported 06/30/2026 1237322209
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,045.40 06/13/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO
Fruquintinib No dispute reported 06/30/2026 1223281234
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,965.00 05/28/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO INC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223280384
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 05/28/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO INC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223280386
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,514.47 05/15/2025 Non-covered Recipient Entity
Fdi Clinical Research
A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma No dispute reported 06/30/2026 1235997405
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 05/12/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO INC
AN OPEN-LABEL, DOSE ESCALATION, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-676 AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS No dispute reported 06/30/2026 1223279388
Principal investigator 1 Mirati Therapeutics, Inc. $13,631.97 04/28/2025 Non-covered Recipient Entity
Fundacion De Investigacion
A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy No dispute reported 06/30/2026 1236531120
Principal investigator 1 Organon Llc $500.00 04/14/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO
8415-060 No dispute reported 06/30/2026 1173042250
Principal investigator 1 Organon Llc $9,943.92 04/07/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO
8415-060 No dispute reported 06/30/2026 1173042244
Principal investigator 1 Organon Llc $3,400.00 04/07/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO
8415-060 No dispute reported 06/30/2026 1173042246
Principal investigator 1 Mirati Therapeutics, Inc. $7,548.84 03/21/2025 Non-covered Recipient Entity
Fundacion De Investigacion
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) No dispute reported 06/30/2026 1236531116
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $21,375.00 03/05/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO
Fruquintinib No dispute reported 06/30/2026 1223276049
Principal investigator 1 TOLMAR, INC. $765.00 02/21/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC.
TOL2506A No dispute reported 06/30/2026 1237322031
Principal investigator 1 TOLMAR, INC. $742.50 02/21/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC.
TOL2506A No dispute reported 06/30/2026 1237322034
Principal investigator 1 TOLMAR, INC. $2,500.00 02/21/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC.
TOL2506A No dispute reported 06/30/2026 1237322037
Principal investigator 1 TOLMAR, INC. $2,000.00 02/21/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC.
TOL2506A No dispute reported 06/30/2026 1237322040
Principal investigator 1 TOLMAR, INC. $650.00 02/21/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC.
TOL2506A No dispute reported 06/30/2026 1237322043
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,108.19 02/20/2025 Non-covered Recipient Entity
Fdi Clinical Research
A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination with Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma No dispute reported 06/30/2026 1235997409
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,434.00 02/11/2025 Non-covered Recipient Entity
Fundacion De Investigacion De Diego
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma after Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 1235997263
Principal investigator 1 TOLMAR, INC. $650.00 01/24/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC.
TOL2506A No dispute reported 06/30/2026 1237322014
Principal investigator 1 TOLMAR, INC. $2,500.00 01/24/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC.
TOL2506A No dispute reported 06/30/2026 1237322017
Principal investigator 1 TOLMAR, INC. $765.00 01/24/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC.
TOL2506A No dispute reported 06/30/2026 1237322021
Principal investigator 1 TOLMAR, INC. $2,000.00 01/24/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC.
TOL2506A No dispute reported 06/30/2026 1237322024
Principal investigator 1 TOLMAR, INC. $2,500.00 01/24/2025 Non-covered Recipient Entity
FUNDACION DE INVESTIGACION DE DIEGO INC (FDI) - . DIEGO RESEARCH FOUNDATION INC.
TOL2506A No dispute reported 06/30/2026 1237322283